R

Redmile Group portfolio

Redmile Group has 4 portfolio companies on record at Recent Funding. It led 1 of the 6 rounds it joined. Its most recent investment on record is Star Therapeutics's $125M Series B+ round in October 2025, alongside Westlake Village BioPartners, Viking Global Investors, Soleus Capital and 6 others. By category, its portfolio leans toward Health and bio (4) and Data and analytics (1). It has co-invested with Cormorant Asset Management, Qatar Investment Authority and RA Capital Management, most often Cormorant Asset Management (3 rounds).

What Redmile Group invests in

• Health and bio · 4 · 100%
• Data and analytics · 1 · 25%
• Logistics and mobility · 1 · 25%

Redmile Group recent investments

Company	Round	Date	Alongside
SStar Therapeutics	Series B+ · $125M	Oct 1, 2025	Westlake Village BioPartners, Viking Global Investors (lead), Soleus Capital +6
AAgomab Therapeutics	Series B+ · $95.45M	Oct 11, 2023	Walleye Capital, Pontifax, Pfizer +6
SStar Therapeutics	Series B+ · $90M	Sep 5, 2023	Westlake Village BioPartners, Soleus Capital, Sofinnova Investments (lead) +6
OOrbital Therapeutics	Series A · $270M	Apr 26, 2023	Rellim Capital Management, Newpath Management, Moore Strategic Ventures +6
AAgomab Therapeutics	Series B+ · $74M · lead	Mar 10, 2021	V-Bio Ventures, Pontifax, OMNES Capital +4
AAtreca	Series B+ · $125M	Sep 12, 2018	Wellington Management (lead), Tekla Capital Management, Tavistock Life Sciences +5

How Redmile Group invests

Share is of the 6 rounds on Recent Funding that name Redmile Group. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Redmile Group portfolio companies

• SStar Therapeutics$125MSeries B+ · Oct 2025
• AAgomab Therapeutics$95.45MSeries B+ · Oct 2023
• OOrbital Therapeutics$270MSeries A · Apr 2023
• AAtreca$125MSeries B+ · Sep 2018

Company	Round with Redmile Group	Total raised	Latest raise
SStar Therapeutics Health and bio	Oct 1, 2025 Series B+ · $125M	$215M	Oct 1, 2025 Series B+
AAgomab Therapeutics Health and bio	Oct 11, 2023 Series B+ · $95.45M	$193.45M	Oct 11, 2023 Series B+
OOrbital Therapeutics Health and bio	Apr 26, 2023 Series A · $270M	$270M	Aug 3, 2025 Series A
AAtreca Health and bio	Sep 12, 2018 Series B+ · $125M	$181M	Feb 5, 2026 Series A

Most frequent co-investors

• CCormorant Asset Management3 shared rounds · last Oct 11, 2023
• QQatar Investment Authority2 shared rounds · last Oct 1, 2025
• RRA Capital Management2 shared rounds · last Oct 1, 2025
• SSofinnova Investments2 shared rounds · last Oct 1, 2025
• OOrbiMed2 shared rounds · last Oct 1, 2025
• SSoleus Capital2 shared rounds · last Oct 1, 2025
• NNYBC Ventures2 shared rounds · last Oct 1, 2025
• WWestlake Village BioPartners2 shared rounds · last Oct 1, 2025
• PPontifax2 shared rounds · last Oct 11, 2023
• VViking Global Investors1 shared round · last Oct 1, 2025
• SSanofi Ventures1 shared round · last Oct 1, 2025
• CCanaan Partners1 shared round · last Oct 11, 2023

Similar investors

• BBain Capital Life Sciences4 companies · 3 deals in 12 mo
• DDuquesne Family Office4 companies · 3 deals in 12 mo
• QQatar Development Bank4 companies · 3 deals in 12 mo
• TThe Column Group4 companies · 3 deals in 12 mo
• AAdage Capital Management4 companies · 2 deals in 12 mo
• AAsabys Partners4 companies · 2 deals in 12 mo

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

Portfolio companies are the companies on Recent Funding with a round that lists Redmile Group, which is a subset of its real portfolio. API: /api/v1/investors/redmile-group (get a free API key). More: the most active VC firms and new venture capital funds.